Latest news with #KymeraTherapeutics
Yahoo
11-08-2025
- Business
- Yahoo
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.46%. A quarter ago, it was expected that this company would post a loss of $0.92 per share when it actually produced a loss of $0.82, delivering a surprise of +10.87%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kymera Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.48 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 66.7%. This compares to year-ago revenues of $25.65 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Kymera Therapeutics shares have added about 1% since the beginning of the year versus the S&P 500's gain of 8.6%. What's Next for Kymera Therapeutics? While Kymera Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Kymera Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.92 on $16.74 million in revenues for the coming quarter and -$3.39 on $80.99 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Codexis (CDXS), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 13. This producer of custom industrial enzymes is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +46.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Codexis' revenues are expected to be $14.96 million, up 87.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report Codexis, Inc. (CDXS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
28-06-2025
- Business
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
28-06-2025
- Business
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Kymera weakness a buying opportunity, says Stifel
Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following 'a slate of updates,' including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new partnership deal with Gilead (GILD) for a CDK2 molecular glue degrader. While the update related to IRAK4 is 'disappointing and removes potential catalysts' next year, Sanofi expects to move KT-485 into Phase 1 next year and the broader partnership remains in place, notes the analyst. On the Gilead deal, Kymera will receive up to $85M in upfront and options, adds the analyst, who would view any weakness from today's news as a buying opportunity as the firm contends there remains limited credit in the stock for the broader pipeline and additional milestone payments. Stifel has a Buy rating on Kymera shares, which are down $1.18, or 2.5%, to $45.96 in morning trading. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on KYMR: Disclaimer & DisclosureReport an Issue Morning Movers: General Mills dips following fourth quarter report Kymera Therapeutics Partners with Gilead for Oncology Treatment Kymera Therapeutics Advances KT-485 in Sanofi Collaboration Gilead sees Kymera deal lowering 2025 EPS by 2c-3c Gilead, Kymera enter license agreement for molecular glue degrader program
Reuters
25-06-2025
- Business
- Reuters
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
June 25 (Reuters) - Gilead Sciences (GILD.O), opens new tab has entered into an option and license deal with Kymera Therapeutics (KYMR.O), opens new tab to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal, Gilead would pay as much as $750 million, including up to $85 million upfront, in exchange for an option to gain global rights to develop, manufacture and sell Kymera's drug candidates that belong to a class called molecular glue degraders. Kymera is also eligible to receive tiered royalties on net sales of the drugs under the deal. Compared to traditional cancer drugs that inhibit the action of an associated protein, Kymera's drugs are designed to selectively eliminate proteins called CDK2, or cyclin-dependent kinase 2. "This mechanism aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue," said Flavius Martin, executive vice president of research at Gilead. Kymera said it would lead all research activities for the drugs currently tested in preclinical studies and advance it as a potential treatment for breast cancer and other solid tumors. The deal with Kymera is expected to reduce Gilead's 2025 profit per share by about two to three cents, the companies said.
